Navigation Links
Tarantula venom-based MD therapy to be advanced by UB scientists' biotech company
Date:12/29/2009

dminister the drug. The peptide and its mirror image are covered by U.S. patents obtained by UB's Office of Science, Technology Transfer and Economic Outreach (STOR), and licensed to Rose Pharmaceuticals. Sachs noted that there are no other drugs known to act specifically on mechanosensitive ion channels, the target of GsMTx4.

"Unlike most drugs, GsMTx4 seems to generate only positive side effects," said Sachs. "In addition to its effectiveness in MD, it inhibits atrial fibrillation, a cardiac arrhythmia that affects 2 million Americans, and for which there currently is no reliable drug therapy.

"In a second application, research groups in Korea and UC San Francisco have shown that GsMTx4 can inhibit mechanically induced pain (pain originating in nerve fibers)," he said. "This therapy is at least half as effective as morphine, but does not act on the brain, only at the site of increased sensitivity." Mark Kristal, PhD, UB professor of psychology, has been collaborating on the pain testing.

GsMTx4 appears to have additional applications. Robert Plunkett, MD., UB associate professor of neurosurgery, has shown that the peptide stimulates neuronal growth, and may be useful for the treatment of Parkinson's disease.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Page: 1 2

Related biology news :

1. Successful stem cell therapy for treatment of eye disease
2. Gene therapy and stem cells save limb
3. New therapy targets for amyloid disease
4. New understanding about mechanism for cell death after stroke leads to possible therapy
5. Duke develops nano-scale drug delivery for chemotherapy
6. Caltech researchers show efficacy of gene therapy in mouse models of Huntingtons disease
7. USU scientists report major advance in human antibody therapy against deadly Nipah virus
8. Patients in Europe benefit from new radiation therapy
9. LX211 highlighted as potential disease modifying therapy for non-infectious uveitis
10. Research needed to learn which DCIS patients may be candidates for less invasive therapy
11. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... scientists from 25 countries and 35 states will ... the Genetics Society of America (GSA) next week ... conference will feature close to 500 presentations (including ... including gene expression and regulation, functional genomics, chemical ... and a variety of diseases. , Of ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
(Date:7/25/2014)... KANSAS CITY, MOResearchers at the Stowers Institute for ... classes of pheromone receptors, and found pheromones crucial to ... one class of receptors helps a male mouse detect ... other class of receptors lets him know if the ... sets of pheromones are critical to trigger mating. Stowers, ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2It takes two to court 2It takes two to court 3
... loss of dopamine neurons is a hallmark of many ... Stem cell biology and regenerative medicine offer novel therapies ... the online open-access journal PLoS Biology Dr. Raja Kittappa, ... McKay show that the transcription factor FOXA2 plays a ...
... invasive plant species is complex, to say the least. ... create conditions that promote population explosions of invasive plants, ... to the ecosystems they inhabit. On the other, fire ... growth. A new general technical report published by ...
... New microscopic pictures show the first-ever physical evidence ... (CF) disease. Researchers at the University of Alabama ... protein called epithelial sodium channel, or ENaC. Both proteins ... exactly what role each plays is unclear. ...
Cached Biology News:Cystic fibrosis proteins photographed interacting 2
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Potential Future Application of Stem Cells as a ... Treatment for Diabetes ... Nature Biotechnology, SAN DIEGO, Feb. 20 Novocell, Inc., a stem cell,engineering ... cells can be turned into pancreatic cells,capable of producing insulin in mice. The ...
... PPD, Inc. (Nasdaq:,PPDI) today announced its plans to begin ... common stock may be purchased from time to time,in the ... a share repurchase program in,view of the current price at ... balance sheet and its ability to generate cash,as well as ...
... Rotarix Would be the Only Vaccine Indicated to Prevent, ... Circulating Types, Offering, Completion of the Vaccination by ... GAITHERSBURG, Md. and PHILADELPHIA, Feb. 20 ,GlaxoSmithKline (NYSE: ... Drug,Administration,s (FDA) Vaccines and Related Biological Products Advisory,Committee (VRBPAC) ...
Cached Biology Technology:Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 2Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 3PPD Announces Plan to Repurchase Shares of its Common Stock 2GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 2GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 3GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 4
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: